Archives of Ophthalmology · 1988 · 354 citations · 46 references
MedicineOphthalmologyVision ScienceOcular DiseaseOcular PharmacologyVisual DisordersAge-related Macular DegenerationAge-related Visual ImpairmentMacular DegenerationRetinal Pigment EpitheliumVisual ImpairmentZinc MetabolismMacular Degeneration Vision LossMacular ToxicityPlacebo-controlled Efficacy AssessmentReduced Visual AcuityRetinal Pigment Epithelium PhysiologyVisual Function LossZinc BiochemistryZinc Ingestion
Macular degeneration, a leading cause of severe visual loss in older adults, is linked to age and drusen, but its etiology remains unclear, with zinc‑rich retinal layers implicated in the disease process. The study aimed to evaluate the effect of oral zinc on visual acuity in 151 patients with drusen or macular degeneration through a prospective, randomized, double‑masked, placebo‑controlled trial. The investigators administered oral zinc in a prospective, randomized, double‑masked, placebo‑controlled design to 151 subjects with drusen or macular degeneration, measuring visual acuity outcomes. Over 12–24 months, zinc‑treated eyes experienced significantly less visual loss than placebo, demonstrating a modest but positive treatment effect, yet due to the study’s pilot nature and potential toxicity, widespread zinc use is not yet recommended.
• Macular degeneration associated with age and drusen, an important cause of severe visual loss in older persons, is of unknown cause. The sensory retina and retinal pigment epithelium, which are cell layers in zinc, appear to be prominently involved in the disease process. Because zinc plays a role in the metabolic function of several important enzymes in the chorioretinal complex, we undertook a prospective, randomized, double-masked, placebo-controlled investigation of the effects of oral zinc administration on the visual acuity outcome in 151 subjects with drusen or macular degeneration. Although some eyes in the zinc-treated group lost vision, this group had significantly less visual loss than the placebo group after a follow-up of 12 to 24 months. This is the first controlled oral intervention study to show a positive, if limited, treatment effect in macular degeneration, a major public health problem. Because of the pilot nature of the study and the possible toxic effects and complications of oral zinc administration, widespread use of zinc in macular degeneration is not now warranted.
46
Statistical Methods for Research Workers
American Journal of Clinical Pathology · 1945 · 11.1K citations
New Visual Acuity Charts for Clinical Research
Frederick L. Ferris, Aaron Kassoff, George H. Bresnick et al. · American Journal of Ophthalmology · 1982 · 2.2K citations
Medicine, Ophthalmology, Optometry +11
Harold A. Kahn, Howard M. Leibowitz, James P. Ganley et al. · American Journal of Epidemiology · 1977 · 760 citations
SENILE MACULAR DEGENERATION: A CASE-CONTROL STUDY
Leslie Hyman, Abraham M. Lilienfeld, Frederick L. Ferris et al. · American Journal of Epidemiology · 1983 · 592 citations